RedHill Biopharma’s RHB-104 orally-administered antibiotic combination therapy has achieved its primary endpoint and key secondary endpoints in phase III Crohn’s disease study.
Destiny Pharma, a UK-based clinical stage biotechnology company, has reported positive data for its synthetic antimicrobial drug XF-73 from a phase 1 skin irritation study.
Takeda’s lung cancer drug Alunbrig (brigatinib) has significantly improved progression-free survival (PFS) in phase 3 ALTA-1L (ALK in lung cancer trial of AP26113 in 1st line) trial.
Hutchison China MediTech (Chi-Med) has commenced a phase Ib/II proof-of-concept study in the US to evaluate its small molecule angio-immuno kinase inhibitor sulfatinib in pancreatic neuroendocrine tumors (NET) and biliary tract cancer (BTC).
Leap Therapeutics has signed a deal to evaluate its immuno-oncology compound TRX518 in combination with Merck and Pfizer’s avelumab, and chemotherapy for the treatment of advanced solid tumors.
Boehringer Ingelheim and Eli Lilly and Company reported that the CARMELINA cardiovascular outcome trial evaluating their diabetes drug Tradjenta met its primary endpoint.
Pfizer and Eli Lilly’s osteoarthritis (OA) pain drug, tanezumab, has met all three co-primary endpoints in a phase 3 study.
A phase III CAPSTONE-2 study has demonstrated that baloxavir marboxil reduced symptoms in people at high risk of complications from the flu.
A failure in a phase 1 clinical program has forced Zynerba Pharmaceuticals to stop development of ZYN001, its pro-drug of tetrahydrocannabinol (THC) intended for the treatment of neuropsychiatric disorders including Tourette Syndrome.
Anavex Life Sciences has secured approval from the Australian Human Research Ethics Committee to begin its phase 2b/3 trial of Anavex 2-73 to treat early Alzheimer’s disease.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.